Search
forLearn
5 / 801 resultslearn Amalaki
learn Allantoin
learn AminoMar™
learn amino acids blend
Research
5 / 1000+ resultsresearch Pharmaceutical care in transplantation: current challenges and future opportunities
Pharmaceutical care in transplantation faces challenges but has promising future opportunities for better outcomes.
research A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae
The genus Sophora has compounds with potential health benefits and could lead to new drugs, but more research is needed to understand their effects and safety.
research A férfi és női testek medikalizációja a XIX. századtól napjainkig
Medicalization has shaped how society views health and gender roles over the past 200 years.
research AMALAKI (EMBLICA OFFICINALIS GAERTN.): AN INTEGRATIVE REVIEW AND META-ANALYSIS OF CLASSICAL AYURVEDIC PERSPECTIVES AND MODERN CLINICAL EVIDENCE
Amalaki improves health in many areas, including cholesterol, blood sugar, and liver function, with no serious side effects.
research AMALAKI (EMBLICA OFFICINALIS GAERTN.): AN INTEGRATIVE REVIEW AND META-ANALYSIS OF CLASSICAL AYURVEDIC PERSPECTIVES AND MODERN CLINICAL EVIDENCE
Amalaki improves cholesterol, blood sugar, inflammation, and liver function without serious side effects.
Community Join
5 / 1000+ resultscommunity ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.